StockWatch
·

MYRIAD GENETICS INC Q1 FY26 Results

MYGNQ1 FY26 Results
Filing
MetricValue ($ M)Q1 FY25
Revenue200.402.3%
Total Income200.402.3%
Expenditure231.102.8%
PBT-34.1016.0%
Net Profit-34.1034000.0%
OPM-15.32%0.52pp
NPM-17.02%16.96pp
EPS-0.36
View full financials

Myriad Genetics Reports Q1 2026 Revenue of $200.4M, Up 2% Y-o-Y

06 May 2026 · 6 May, 1:43 am

Summary

Myriad Genetics announced its first quarter 2026 financial results, reporting revenue of $200.4 million, a 2% increase year-over-year. The company saw growth in Cancer Care Continuum and Mental Health testing volumes, offset by a decline in Prenatal Health. The launch of Precise MRD and FDA approval of MyChoice CDx were key milestones. Myriad Genetics reaffirmed its financial guidance for the full-year 2026, expecting revenue between $860 and $880 million.

Key Highlights

  1. 1

    Myriad Genetics' first quarter 2026 revenue reached $200.4 million, reflecting a 2% increase year-over-year.

  2. 2

    Test volume in the first quarter of 2026 remained stable, with growth in Cancer Care Continuum and Mental Health offset by a decline in Prenatal Health.

  3. 3

    The company launched Precise Molecular Residual Disease (MRD), an ultrasensitive assay, to improve cancer patient outcomes.

  4. 4

    FDA approval was received for the MyChoice CDx test as a companion diagnostic for Zejula® in advanced ovarian cancer patients.

  5. 5

    Gross margin for the first quarter of 2026 was 68.7%, an increase of 20.0 basis points from the first quarter of 2025.

  6. 6

    The company's GAAP net loss for the first quarter of 2026 was $34.1 million, or $0.36 per share.

  7. 7

    Myriad Genetics reaffirmed its financial guidance for the full-year 2026.

Management Comments

S

Sam Raha

"We are seeing strong performance across a number of key areas, including the Cancer Care Continuum as we begin to realize a return on our focused strategy. We have implemented a dedicated hereditary cancer sales force and other key programs designed to support the expected continued growth in germline testing. And with decisive steps taken to address our Prenatal Health business, we expect improved performance in the remainder of 2026." "Our limited launch of Precise MRD for breast cancer patients has received positive early feedback and we remain on track with our other planned launches in 2026, as part of our milestone-rich year. We are confident these tests will be important drivers of our growth in 2027 and beyond."

Informational and educational content only. Not investment advice.